About: covid:PMC7445147

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: covid:PMC7445147 Goto Sponge NotDistinct Permalink

An Entity of Type : owl:Thing, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
Creator	Ahmadinejad, Zahra Ghiasvand, Fereshteh Hajiabdolbaghi, Mahboubeh Jafari, Fatemeh Jafari, Sirous Khalili, Hosein Kouchak, Hamid Manafi, Navid Pirhayati, Mohammad Sadr, Sara Salehi, Mohamadreza Seifi, Arash Sekhavati, Ehsan SeyedAlinaghi, SeyedAhmad Tabarestani, Mohammad Zendehdel, Abolfazl Siahkali, Saeidreza Golestan, Fereshteh
is schema:about of	named entity 'Azithromycin' named entity 'RANDOMIZED TRIAL' named entity 'OPEN' named entity 'Effectiveness' named entity 'randomized trial' named entity 'Azithromycin' named entity 'antiviral treatment' named entity 'clinical trial' named entity 'SARS-CoV-2' named entity 'QTc' named entity 'COVID' named entity 'mortality rate' named entity 'COVID-19' named entity 'azithromycin' named entity 'torsade de pointes' named entity 'control group' named entity 'oxygen saturations' named entity 'combination therapy' named entity 'Windows' named entity 'statistical significance' named entity 'coronavirus' named entity 'American College of Cardiology' named entity 'azithromycin' named entity 'treatment group' named entity 'medical professionals' named entity 'received no treatment' named entity 'hydroxychloroquine' named entity 'antiviral therapy' named entity 'cohort study' named entity 'coronavirus' named entity 'laboratory investigations' named entity 'ACC' named entity 'SpO2' named entity 'hypersensitivity reactions' named entity 'sample size' named entity 'COVID-19' named entity 'QT interval prolongation' named entity 'France' named entity 'Hydroxychloroquine' named entity 'chloroquine' named entity 'RT-PCR test' named entity 'hydroxychloroquine' named entity 'potency' named entity 'protease inhibitors' named entity 'SARS' named entity 'CBC' named entity 'Helsinki' named entity 'informed consent' named entity 'hazard ratio' named entity 'azithromycin' named entity 'radiographic imaging' named entity 'long-term' named entity 'ICU' named entity 'global pandemic of COVID-19' named entity 'kaletra' named entity 'effect size' named entity 'MERS' named entity 'SpO2' named entity 'confidence interval' named entity 'ACC' named entity 'azithromycin' named entity 'human immunodeficiency virus' named entity 'azithromycin' named entity 'synergetic' named entity 'QTc interval' named entity 'hydroxychloroquine' named entity 'TdP' named entity 'treatment groups' named entity 'effect size' named entity 'headache' named entity 'monotherapy' named entity 'azithromycin' named entity 'serum electrolytes' named entity 'azithromycin' named entity 'allergic reactions' named entity 'control group' named entity 'infection' named entity 'hydroxychloroquine' named entity 'azithromycin' named entity 'COVID-19' named entity 'mortality rate' named entity 'Ebola'

Attributes

Values

Creator

Ahmadinejad, Zahra
Ghiasvand, Fereshteh
Hajiabdolbaghi, Mahboubeh
Jafari, Fatemeh
Jafari, Sirous
Khalili, Hosein
Kouchak, Hamid
Manafi, Navid
Pirhayati, Mohammad
Sadr, Sara
Salehi, Mohamadreza
Seifi, Arash
Sekhavati, Ehsan
SeyedAlinaghi, SeyedAhmad
Tabarestani, Mohammad
Zendehdel, Abolfazl
Siahkali, Saeidreza
Golestan, Fereshteh

is schema:about of

named entity 'Azithromycin'
named entity 'RANDOMIZED TRIAL'
named entity 'OPEN'
named entity 'Effectiveness'
named entity 'randomized trial'
named entity 'Azithromycin'
named entity 'antiviral treatment'
named entity 'clinical trial'
named entity 'SARS-CoV-2'
named entity 'QTc'
named entity 'COVID'
named entity 'mortality rate'
named entity 'COVID-19'
named entity 'azithromycin'
named entity 'torsade de pointes'
named entity 'control group'
named entity 'oxygen saturations'
named entity 'combination therapy'
named entity 'Windows'
named entity 'statistical significance'
named entity 'coronavirus'
named entity 'American College of Cardiology'
named entity 'azithromycin'
named entity 'treatment group'
named entity 'medical professionals'
named entity 'received no treatment'
named entity 'hydroxychloroquine'
named entity 'antiviral therapy'
named entity 'cohort study'
named entity 'coronavirus'
named entity 'laboratory investigations'
named entity 'ACC'
named entity 'SpO2'
named entity 'hypersensitivity reactions'
named entity 'sample size'
named entity 'COVID-19'
named entity 'QT interval prolongation'
named entity 'France'
named entity 'Hydroxychloroquine'
named entity 'chloroquine'
named entity 'RT-PCR test'
named entity 'hydroxychloroquine'
named entity 'potency'
named entity 'protease inhibitors'
named entity 'SARS'
named entity 'CBC'
named entity 'Helsinki'
named entity 'informed consent'
named entity 'hazard ratio'
named entity 'azithromycin'
named entity 'radiographic imaging'
named entity 'long-term'
named entity 'ICU'
named entity 'global pandemic of COVID-19'
named entity 'kaletra'
named entity 'effect size'
named entity 'MERS'
named entity 'SpO2'
named entity 'confidence interval'
named entity 'ACC'
named entity 'azithromycin'
named entity 'human immunodeficiency virus'
named entity 'azithromycin'
named entity 'synergetic'
named entity 'QTc interval'
named entity 'hydroxychloroquine'
named entity 'TdP'
named entity 'treatment groups'
named entity 'effect size'
named entity 'headache'
named entity 'monotherapy'
named entity 'azithromycin'
named entity 'serum electrolytes'
named entity 'azithromycin'
named entity 'allergic reactions'
named entity 'control group'
named entity 'infection'
named entity 'hydroxychloroquine'
named entity 'azithromycin'
named entity 'COVID-19'
named entity 'mortality rate'
named entity 'Ebola'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software